drugset / Trial / NCT01781806
A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
Phase 4
Completed
328 enrolled
University of California, Los Angeles
AIDS Project Los Angeles · collabLos Angeles County Department of Public Health · collabLos Angeles LGBT Center · collabThe OASIS Clinic · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the safety, acceptability and feasibility of delivery of Pre-Exposure Prophylaxis (PrEP) or Post-Exposure Prophylaxis) PEP as part of combination HIV prevention services for high-risk MSM and transgender women.
Timeline
- Start
- 2013-05
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Tenofovir | Small molecule | 300 mg | Oral |
| Comparator | emtricitabine | Other / unclassified | 200 mg | Oral |
Indications
No indication recorded.